EWA
FBLG icon

EverSource Wealth Advisors’s FibroBiologics FBLG Stock Holding History

EverSource Wealth Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$28 – 4473
2025
Q3 		$28 Sell
3
-3
-50% -$36 ﹤0.01% 4278
2025
Q2 		$76 Sell
6
-2
-25% -$36 ﹤0.01% 4158
2025
Q1 		$139 Buy
+8
New +$229 ﹤0.01% 3768

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ANTB
AMG National Trust Bank Greenwood Village, Colorado $4.61B AUM 19.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverSource Wealth Advisors's FBLG Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of FibroBiologics (FBLG) in Q4 2025, closing a stake of 3 shares — an estimated $28 sold.

EverSource Wealth Advisors first reported a position in FBLG in Q1 2025 and held it in 3 quarters. The position peaked at $139 in Q1 2025. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining FibroBiologics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 3 FibroBiologics shares in Q4 2025, an estimated $28.
  • EverSource Wealth Advisors first reported a position in FibroBiologics in Q1 2025 and held it in 3 quarters.
  • EverSource Wealth Advisors's FibroBiologics position peaked at $139 in Q1 2025.
  • 45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.